← Back to Screener
Biodexa Pharmaceuticals plc American Depositary Shs (BDRX)
Price$4.33
Favorite Metrics
Price vs S&P 500 (26W)-101.17%
Price vs S&P 500 (4W)-10.06%
Market Capitalization$2.13M
All Metrics
Book Value / Share (Quarterly)$0.00
P/TBV (Annual)0.65x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.00
Price vs S&P 500 (YTD)-73.48%
Net Profit Margin (TTM)-1858.01%
EPS (TTM)$-0.01
10-Day Avg Trading Volume0.19M
EPS Excl Extra (TTM)$-0.01
EPS (Annual)$-0.02
ROI (Annual)-63.31%
Net Profit Margin (5Y Avg)-2372.66%
Cash / Share (Quarterly)$0.00
ROA (Last FY)-38.76%
EBITD / Share (TTM)$-0.01
ROE (5Y Avg)-168.97%
Operating Margin (TTM)-2103.41%
Cash Flow / Share (Annual)$-0.03
P/B Ratio0.10x
P/B Ratio (Quarterly)0.28x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-53.58x
ROA (TTM)-42.07%
EPS Incl Extra (Annual)$-0.02
Current Ratio (Annual)1.75x
Quick Ratio (Quarterly)3.63x
3-Month Avg Trading Volume0.45M
52-Week Price Return-95.23%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.00
P/S Ratio (Annual)3.05x
Asset Turnover (Annual)0.04x
52-Week High$96.50
Operating Margin (5Y Avg)-2597.68%
EPS Excl Extra (Annual)$-0.02
CapEx CAGR (5Y)19.40%
26-Week Price Return-92.43%
Quick Ratio (Annual)0.47x
13-Week Price Return-66.70%
Total Debt / Equity (Annual)0.09x
Current Ratio (Quarterly)3.63x
Enterprise Value$-3.208
Asset Turnover (TTM)0.04x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-1964.57%
Cash / Share (Annual)$0.00
3-Month Return Std Dev124.00%
Net Income / Employee (TTM)$-1
ROE (Last FY)-68.84%
EPS Basic Excl Extra (Annual)$-0.02
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.04x
EPS Incl Extra (TTM)$-0.01
Receivables Turnover (Annual)0.00x
ROI (TTM)-59.34%
P/S Ratio (TTM)3.05x
Pretax Margin (5Y Avg)-2539.69%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.01
Price vs S&P 500 (52W)-130.33%
Year-to-Date Return-69.34%
5-Day Price Return12.26%
EPS Normalized (Annual)$-0.02
ROA (5Y Avg)-102.56%
Net Profit Margin (Annual)-1858.01%
Month-to-Date Return12.62%
EBITD / Share (Annual)$-0.02
Operating Margin (Annual)-2103.41%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-153.97%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.01
P/TBV (Quarterly)0.56x
P/B Ratio (Annual)0.21x
Pretax Margin (TTM)-1964.57%
Book Value / Share (Annual)$0.02
Price vs S&P 500 (13W)-69.56%
Beta1.27x
Revenue / Share (TTM)$0.00
ROE (TTM)-63.03%
52-Week Low$2.86
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
BDRXBiodexa Pharmaceuticals plc American Depositary Shs | 3.05x | — | — | — | $4.33 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Biodexa Pharmaceuticals develops therapies targeting diseases with significant unmet medical needs. The clinical-stage company's pipeline spans familial adenomatous polyposis, non-muscle invasive bladder cancer, type 1 diabetes, and orphan brain cancers.